Fundraising FoxHealthtech Startups
18,755 companies tagged Healthtech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Imago Systems develops Visual Intelligence (VI) image classification technology that processes medical images and converts unstructured image content into structured data for detection and diagnosis. It targets healthcare imaging verticals including mammography, cardiology image analysis, COVID-19 X-ray/ultrasound analysis, contract research organizations, and animal diagnostics, positioning itself as a processing layer for existing imaging equipment and AI systems.
0 investors
Imanis Life Sciences is a contract research organization staffed by virologists, immunologists, molecular biologists, and assay scientists that provides laboratory and development services to help clients accelerate therapy development.
0 investors
0 investors
0 investors
0 investors
Immunaeon provides cellular banking and cryopreservation services, helping individuals preserve their healthiest cells for potential future medical use. The company serves patients seeking to maintain medical options through cell preservation, with an emphasis on clear communication and privacy protection.
0 investors
Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
0 investors
ImmuneSensor Therapeutics is a clinical-stage biotechnology company developing orally available small molecule cGAS inhibitors that target the cGAS-STING innate immune pathway to treat inflammatory and autoimmune diseases. Founded on research from UT Southwestern Medical Center, it advances a pipeline of drug candidates for immune-related conditions.
0 investors
0 investors
ImmunoMet Therapeutics is a clinical-stage oncology drug developer working to advance lixumistat, a compound targeting oxidative phosphorylation in cancer to address resistance to existing treatments. Founded in 2015 as a spin-off from HanAll Biopharma, the company runs its clinical programs with specialist CROs and partners, including trials at MD Anderson Cancer Center.
0 investors
0 investors
0 investors